FDA approval of ibalizumab, fostemsavir, and lenacapavir offers encouraging options for virologic suppression and immune restoration for patients with HIV who are heavily treatment-experienced and/or who have multidrug-resistant HIV-1. However, integrating these novel antiretroviral agents into practice is complex.

The consensus recommendations for the use of novel antiretrovirals in persons with HIV who are heavily treatment-experienced and/or who have multidrug-resistant HIV-1 were developed by a multidisciplinary panel of experts in infectious diseases led by ACCP members David B. Cluck and Daniel B. Chastain. The recommendations have been reviewed and endorsed by the American College of Clinical Pharmacy and the American Academy of HIV Medicine and published in the May 2024 issue of Pharmacotherapy.

The consensus recommendations provide an algorithmic approach to major decisions for selecting and monitoring these novel antiretroviral agents. The Consensus Recommendations and Executive Summary are published open access in the May 2024 issue of Pharmacotherapy, an official journal of ACCP.